Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

NCT06563895 is registered in ClinicalTrials.gov with Eidos Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT06563895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06563895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Phase
Phase 3
Overall status
Recruiting
Start date
May 12, 2025
Completion date
December 31, 2032
Enrollment
587 (estimated)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid cardiomyopathy, amyloidosis, cardiomyopathies, heart diseases, polyneuropathies, transthyretin amyloidosis